drug
crinecerfont
Marketedupdated 3mo agoby $NBIX NEUROCRINE BIOSCIENCES INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying crinecerfont
- phase2Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
- phase2Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
- phase3Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
- phase3Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
- phase2Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 13, 2029
~3.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Jun 9, 2041compositionUS 12128033
- Jun 9, 2041compositionUS 12128033
- Jun 9, 2041compositionUS 12128033
- Jun 9, 2041compositionUS 12128033
- Jan 21, 2035method-of-use (U-4049)US 10905690
- Jan 21, 2035method-of-use (U-4049)US 10905690
- Jan 21, 2035method-of-use (U-4049)US 10905690
- Jan 21, 2035method-of-use (U-4049)US 10905690
- Jan 21, 2035method-of-use (U-4049)US 11311544
- Jan 21, 2035method-of-use (U-4049)US 11311544
- Jan 21, 2035method-of-use (U-4049)US 11311544
- Jan 21, 2035method-of-use (U-4049)US 11311544
- Jan 21, 2035method-of-use (U-4049)US 11730739
- Jan 21, 2035method-of-use (U-4049)US 11730739
- Jan 21, 2035method-of-use (U-4049)US 11730739
- Jan 21, 2035method-of-use (U-4049)US 11730739
FDA exclusivities (8)
- Dec 13, 2031ODE-503Orphan Drug (7y)
- Dec 13, 2031ODE-503Orphan Drug (7y)
- Dec 13, 2031ODE-503Orphan Drug (7y)
- Dec 13, 2031ODE-503Orphan Drug (7y)
- Dec 13, 2029NCENew Chemical Entity (5y)3.3y
- Dec 13, 2029NCENew Chemical Entity (5y)3.3y
- Dec 13, 2029NCENew Chemical Entity (5y)3.3y
- Dec 13, 2029NCENew Chemical Entity (5y)3.3y
News(2)
- Novo’s late-stage IL-6 stumble shakes inflammation spaceNovo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s…biospace · 11d ago
- Vertex to acquire Crinetics in $10B foray into endocrine disease drugsVertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.biopharma_dive · 1mo ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that